Morgan Stanley Global Endurance R6 holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Morgan Stanley Global Endurance Portfolio Class R6 MSJSX
- NAV / 1-Day Return 23.15 / −1.87 %
- Total Assets 15.6M
-
Adj. Expense Ratio
0.950%
- Expense Ratio 0.950%
- Distribution Fee Level Above Average
- Share Class Type Retirement, Large
- Category Global Small/Mid Stock
- Investment Style Small Blend
- Min. Initial Investment 5M
- Status Open
- TTM Yield 0.53%
- Turnover 176%
USD | NAV as of Jul 14, 2026 | 1-Day Return as of Jul 14, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MSJSX
Will MSJSX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 51.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Roivant Sciences Ltd Ordinary Shares | 8.73 | 1M | Healthcare |
Victoria PLC | 7.88 | 1M | Consumer Cyclical |
QXO Inc | 5.36 | 833,662 | Industrials |
Teleflex Inc | 5.13 | 797,799 | Healthcare |
Immunovant Inc | 4.66 | 724,459 | Healthcare |
Calumet Inc | 4.65 | 723,636 | Basic Materials |
Arbutus Biopharma Corp | 4.28 | 666,396 | Healthcare |
Appian Corp Class A | 4.18 | 650,440 | Technology |
Floor & Decor Holdings Inc Class A | 3.76 | 585,267 | Consumer Cyclical |
Royalty Pharma PLC Class A | 3.18 | 494,235 | Healthcare |